Anemia - Pipeline Assessment and Market Forecasts to 2017 The Anemia Market is expected to Witness Decline Due to Rising Safety Concerns over ESA Therapies and Weak Late-Stage Pipeline GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a CAGR of 7.4% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. The majority of these therapies were launched between 2001 and 2007 and as a result market growth was pronounced in that period. In 2007, safety concerns over the use of ESAs surfaced and this has led to a decline in sales of the drugs. Since then, growth in the anemia market has been declining. Between 2009 and 2017, the market is expected to decline further as there are no key promising therapies expected to enter the anemia market. Furthermore, biosimilars of ESAs have already entered the European market and are expected to enter the US market between 2009 and 2017. This factor is also expected to restrain the growth of the market. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Anemia--Pipeline-Assessmentand-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare GlobalData evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 60% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. However, the majority of ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market. This shows that there is not strong competition between drugs in the anemia market. Furthermore, the ESAs approved for anemia treatment were found to carry severe cardiovascular side effects, and the FDA consequently issued guidelines about the safety of these therapies. These guidelines are expected to diminish the prescription volume of ESA therapies. Hence, the current competition in the anemia market is estimated to be weak. GlobalData analyzed the pipeline in the anemia market and concluded that the pipeline is very weak. There are only 27 molecules in clinical development. Phase III clinical development includes six molecules and contributes to 22.2% of the anemia pipeline. Phase II clinical development includes 15 molecules and accounts for 55.6% of the anemia pipeline. The early stage development pipeline (the Phase I, preclinical and discovery stages) includes only six molecules. GlobalData, the industry analysis specialist, has released its new report, “Anemia Pipeline Assessment and Market Forecasts to 2017�. The report is an essential source of
information and analysis on the global Anemia market. The report identifies the key trends shaping and driving the global Anemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Anemia--Pipeline-Assessmentand-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782